Emergent

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

Emergent Cold LatAm Acquires Red Polar

Retrieved on: 
Monday, February 5, 2024

Emergent Cold Latin America (“Emergent Cold LatAm” or the “Company”), the region’s largest provider of temperature-controlled storage and logistics solutions, announced today the acquisition of Red Polar, one of the leading cold storage businesses located in Bogotá, Colombia.

Key Points: 
  • Emergent Cold Latin America (“Emergent Cold LatAm” or the “Company”), the region’s largest provider of temperature-controlled storage and logistics solutions, announced today the acquisition of Red Polar, one of the leading cold storage businesses located in Bogotá, Colombia.
  • Founded in 2017, Red Polar operates a single cold storage facility in the municipality of Funza.
  • The Red Polar team is remaining with the business and will benefit from Emergent Cold LatAm’s operational expertise and best practices.
  • Importantly, the Red Polar transaction expands Emergent Cold LatAm’s presence in Bogotá, Colombia’s largest and most populous city.

EMERGENT GLOBAL SOLUTIONS WELCOMES FORMER CALIFORNIA CHP COMMISSIONER WARREN STANLEY AS VICE PRESIDENT OF SECURITY AND JUSTICE

Retrieved on: 
Monday, January 22, 2024

SACRAMENTO, Calif., Jan. 22, 2024 /PRNewswire/ -- Emergent Global Solutions , a leading provider of crisis management and innovative security and justice solutions, today announced the appointment of former California Highway Patrol Commissioner Warren Stanley as the company's new Vice President of Security and Justice.

Key Points: 
  • SACRAMENTO, Calif., Jan. 22, 2024 /PRNewswire/ -- Emergent Global Solutions , a leading provider of crisis management and innovative security and justice solutions, today announced the appointment of former California Highway Patrol Commissioner Warren Stanley as the company's new Vice President of Security and Justice.
  • "We are honored to welcome Warren Stanley to the Emergent Global Solutions team," said Emergent president Mark Ghilarducci .
  • "I am honored to join Emergent Global Solutions and contribute to their mission of providing comprehensive crisis management solutions to our clients and promoting security and justice," said Warren.
  • His appointment reinforces Emergent Global Solutions' commitment to providing unparalleled security and justice solutions to clients.

EMERGENT GLOBAL SOLUTIONS HIRES CHRIS GELDART FORMER WASHINGTON DC DEPUTY MAYOR AS VICE PRESIDENT FOR CRISIS MANAGEMENT

Retrieved on: 
Monday, January 22, 2024

SACRAMENTO, Calif., Jan. 22, 2024 /PRNewswire/ -- Emergent Global Solutions, Inc. , today announced the appointment of former Washington D.C. Deputy Mayor for Public Safety Chris Geldart as Vice President of Crisis Management.

Key Points: 
  • SACRAMENTO, Calif., Jan. 22, 2024 /PRNewswire/ -- Emergent Global Solutions, Inc. , today announced the appointment of former Washington D.C. Deputy Mayor for Public Safety Chris Geldart as Vice President of Crisis Management.
  • "This appointment marks an exciting milestone for Emergent Global Solutions," said Mark Ghilarducci , Emergent CEO.
  • "Chris has a diversified background in emergency and crisis management, and public works.
  • "I am excited to join Emergent Global Solutions and contribute to their mission of crisis management excellence," said Geldart.

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Retrieved on: 
Monday, January 22, 2024

PLYMOUTH MEETING, Pa., Jan. 22, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP). INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner, will be joined by Dr. Simon Best, Otolaryngologist at Johns Hopkins University and a Principal Investigator in INOVIO's Phase 1/2 trial with INO-3107.

Key Points: 
  • The fireside chat, titled "RRP - Disease Treatment Dynamics & Urgent Need for Therapeutic Modalities," will take place on Wednesday, January 24, 2024, at 12:00pm ET.
  • Hartaj Singh, MBA, Managing Director of Biotechnology Equity Research at Oppenheimer & Co. Inc., will moderate the discussion.
  • He is a fellowship-trained laryngeal surgeon whose clinical interests are focused on voice and airway disorders, with a particular interest in RRP.
  • Prior to joining INOVIO, she was the CEO at Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB).

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

Retrieved on: 
Thursday, January 11, 2024

GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.

Key Points: 
  • GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.
  • The new contract with the U.S. Department of Defense (DoD) and led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, is comprised of a five-year base agreement ending on September 30, 2028, and an additional five-year option that would extend the contract to September 30, 2033.
  • “As a part of our mission to protect and enhance lives, Emergent is proud to continue supporting and preparing our nation’s service members who have a high risk of exposure to anthrax bacteria by supplying BioThrax vaccine,” said Paul Williams, senior vice president, products head at Emergent.
  • “This new contract award is a testament to the importance of Emergent’s medical countermeasures portfolio, and we look forward to delivering on our commitments to the U.S. DoD.”
    Under the initial five-year IDIQ contract, there is a guaranteed purchase minimum of $20.1 million, with future orders estimated to be at least $20 million for each following year for a total award value up to $235.8 million.

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

Retrieved on: 
Tuesday, January 9, 2024

GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today announced that Haywood Miller, Interim Chief Executive Officer and Rich Lindahl, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PT.

Key Points: 
  • GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today announced that Haywood Miller, Interim Chief Executive Officer and Rich Lindahl, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PT.
  • The audio link for Emergent's session may be accessed here , and will be live for up to 30 days.
  • The company’s slides will be made available at the time of the presentation on the Investors section of the Emergent website.

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

Retrieved on: 
Tuesday, November 28, 2023

Deliveries are expected to begin this calendar year and be complete by the end of the first quarter of 2024.

Key Points: 
  • Deliveries are expected to begin this calendar year and be complete by the end of the first quarter of 2024.
  • Anthrax is considered a high-priority national security threat and has the potential for major public health impact.
  • In April 2022, Emergent submitted the Biologics License Application to the FDA for review, leading to approval and licensure in July 2023.
  • This latest contract option supplements previous contract procurements and supports the U.S. biodefense preparedness efforts.

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Retrieved on: 
Friday, November 24, 2023

GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission (SEC).

Key Points: 
  • GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission (SEC).
  • Notices are routinely issued by the NYSE in such situations.
  • Under the NYSE’s rules, Emergent will have six months from November 9, 2023 to file the Form 10-Q with the SEC, and can regain compliance with the NYSE listing standards upon filing the Form 10-Q.
  • Because these items also affect subsequent period reporting, the Company must complete this work prior to finalizing its financial statements for the three and nine months ended September 30, 2023 and filing its third quarter Form 10-Q.

AHF: Anthrax Outbreak Exposes Global Health Inequities

Retrieved on: 
Friday, December 22, 2023

“The anthrax outbreak is another example of why we need equity, not charity on global health.

Key Points: 
  • “The anthrax outbreak is another example of why we need equity, not charity on global health.
  • As long as some places have all the resources to respond and others don't—we won't have truly functional pandemic preparedness.
  • “Lower-income countries will continue to suffer from preventable disease outbreaks until big pharma and rich countries prioritize lives over profits.
  • It can be prevented by vaccinating humans and livestock and is not contagious, except in rare cases of cutaneous anthrax.